WHAT’S YOUR PLAN TO TEST FOR RET? Consider NGS to find actionable biomarkers, including RET, in NSCLC and thyroid cancers
INCLUDE RET FUSIONS AND RET POINT MUTATIONS IN YOUR BIOMARKER TESTING PROTOCOL FOR APPROPRIATE PATIENTS
NGS=next-generation sequencing; NSCLC=non-small cell lung cancer; RET=rearranged during transfection. PP-SE-US-0622 04/2021 © Lilly USA, LLC 2021. All rights reserved.
NGS is not one-size-fits-all. NeoGenomics’ diverse portfolio of NGS-based assays enables pathologists to choose the best solution for their oncology testing needs. Wide variety of NGS profiles
19 17 7 5 ３
Optimal sequencing targets
Solid tumor-specific profiles
• DNA for detection of SNVs and indels • RNA for detection of fusions
Fusion panels for solid tumors
Complete disease coverage
Heme cancer-specific profiles
• Solid tumors • Hematologic malignancies
Liquid biopsy profiles
Versatile specimen options
Broad genomic profiles
• Tissue for solid tumors • Bone marrow for hematologic tumors • Liquid biopsy for both
For complete test details, please visit: neogenomics.com/NGS
© 2021 NeoGenomics Laboratories, Inc. All Rights Reserved.
DATIONONE®LIQUID CD FOUN x
FO UN DA TIO NO N
Dx E®C N O ON I T DA N U FO
E® HE
E M
ONE PROVEN PORTFOLIO OF TESTS + SERVICES THAT’S OUR FOUNDATION Foundation Medicine’s proven portfolio of tests and services offers the quality and commitment you need to help inform treatment strategies for all your advanced cancer patients. We offer tissue and blood-based testing for solid tumors, a test for integrated DNA and RNA insights, the option to include IHC for PD-L1 status with tissue testing, and decision support services — providing actionable insights for navigating cancer care. Learn more about Foundation Medicine’s proven portfolio at foundationmedicine.com/portfolio. FoundationOne®Heme is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. FoundationOne Heme has not been cleared or approved by the U.S. Food and Drug Administration. For more information on FoundationOne Heme, please see its Technical Specifications at foundationmedicine.com/heme.. FoundationOne®CDx and FoundationOne®Liquid CDx are qualitative next-generation sequencing based in vitro diagnostic tests for advanced cancer patients with solid tumors and are for prescription use only. FoundationOne CDx utilizes FFPE tissue and analyzes 324 genes as well as genomic signatures. FoundationOne Liquid CDx analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes. The tests are companion diagnostics to identify patients who may benefit from treatment with specific therapies in accordance with the therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the tests does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy for testing with FoundationOne CDx when archival tissue is not available which may pose a risk. Patients who are tested with FoundationOne Liquid CDx and are negative for companion diagnostic mutations should be reflexed to tumor tissue testingand mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com and www.F1LCDxLabel.com. ©2021 Foundation Medicine, Inc. | US-PF-2100065
You st rmpath Choose What You Need A Complete Pathology Software Solution
1.FISH
2.Flow Cytometry
3.Breast
Utilize clear probe signals to diagnose effectively
Provide a complete diagnostic picture for hematological malignancies
Quantify key markers such as HER2 and ER/PR
4.UroVysion
5.Digital Slide Imaging
6.Surgical Biopsies
Go beyond cytology for bladder cancer assessment
View more than 220 antibodies in clear focus
Provide custom reports for GI, GU, Derm, Prostate
7.GYN Cytology Diagnose abnormal Pap screens and build community outreach 481 Edward H Ross Drive Elmwood Park, NJ 07407 | 1 800 627 1479 tel | 1 201 345 7166 fax | www.genpath.com GenPath is a business unit of BioReference Laboratories, Inc. © 2021 All Rights Reserved. BRD003336 - 5/21
Providing fast, actionable results to help you reduce risks, complications and costs Hemostasis Analyzer System The TEG 6s system provides rapid, comprehensive and accurate identification of an individual’s hemostasis condition in a laboratory or site-of-care setting which allows clinicians to drive treatment and monitoring decisions with confidence. The TEG 6s system helps:*
Allow targeted blood therapy to optimize clinical outcomes,
helping to reduce costs
Reduce unnecessary transfusions
Reduce surgical exploration for bleeding
Provide rapid results in time to make decisions
*See teg.haemonetics.com/en/references for citations.
Looking For A Telepathology Solution? Real-Time Telepathology • Tele-Microscopy • Whole Slide Scanning Motic EasyScan Series >> Seamlessly integrate into any workflow, bringing lab-quality scanning to any work environment. >> Share your slides with a single click, or switch to live mode for direct specimen observation.
Motic EasyScan Series
Starting at $16K
PreciPoint M8 >> Take advantage of intuitive workflow. >> Have an overview of the entire slide within seconds and an amazing, large field of view.
PreciPoint M8
>> Access and operate the M8 remotely and in real-time.
Starting at $48K
Need A Clinical Microscope?
Leica DM1000
Leica DM2000
Routine Lab Work
Clinical Applications
Advanced Pathology
(Hematology, Microbiology, Cytology)
(Complex & Routine Pathology & Cytology)
(Features Motorized Nosepiece)
I. Miller carries the latest technology ranging from cameras to remote pathology systems. Experience it firsthand - SCHEDULE YOUR VIRTUAL DEMO TODAY! 215-925-2285 ▪ sales@imillermicroscopes.com
Leica DM3000